WELCOME TO THE INTERNATIONAL CONFERENCE ON LYMPHOCYTE ENGINEERING
The International Conference on Lymphocyte Engineering (ICLE 2018) will provide a dedicated platform to advance research, clinical translation and treatment in immuno-gene therapy. ICLE brings together immunotherapy with cell and gene therapy to foster interdisciplinary collaborations, deepening the connection between basic and clinical research across related disease specialties: oncology, pathogenic diseases, autoimmunity, immunodeficiencies and others.
With unprecedented success from more than 200 clinical trials, the recent increase in investment funding, and FDA approvals of CAR-T therapies, lymphocyte engineering has a potentially significant role in the future of healthcare. Whether you are a scientist, clinical researcher, part of a start-up or an established industry company, ICLE 2018 will be your opportunity to network and discuss immuno-gene therapy with those as excited and passionate about the future as you.
Date: 13 – 15 September 2018
Venue: Meliá Avenida América, Calle de Juan Ignacio Luca de Tena 36, 28027 Madrid, Spain
Why attend
- Participate in the only event that merges all the exciting breakthroughs under one conference – gene therapy, cell therapy, genome engineering, and immunotherapy
- Gain access to quality networking with colleagues advancing related knowledge across diseases
- Meet the thought leaders, who will share invaluable insights on CAR-T Cell and other lymphocyte engineering therapies
- Present your research, clinical findings, therapies and pipeline to a focused international audience
- Become part of the only community across industry and academia dedicated to lymphocyte engineering